Biohacker in your 30s: peptides, NAD+ and the optimisation stack
This is a composite decision situation, not a real patient, testimonial or individual treatment recommendation.
You are healthy, data-driven and slightly impatient. The watch tracks sleep, the bloodwork is quarterly, and the podcast queue keeps insisting the future is already injectable. Your researched question is not “does anything work?” but “which of these actually has human data behind it?” — because the vials arrive with none attached.
What the data says for this situation
The pattern across the optimisation stack is remarkably consistent, and our PubMed counts make it visible. BPC-157: 227 papers, 53 human, zero controlled clinical outcomes. CJC-1295/ipamorelin: hormone elevation confirmed, benefit never tested. NAD+ precursors: biomarker success (NAD+ rises, replicated), clinical endpoints still neutral. Rapamycin: the one with spectacular animal evidence — and an immunosuppressant’s open questions. The stack, read honestly, is a portfolio of mechanisms awaiting outcomes.
Registered aging-intervention trials do exist — our snapshot counts 16 MSC studies under aging-related terms plus the rapamycin and precursor work — so the field is moving; it just moves slower than the market.
Questions worth asking any provider
- For each compound: how many human RCTs, and what did they measure?
- Which lab verifies the purity of what I am injecting?
- What is my stopping rule if bloodwork drifts?
- Am I on anything WADA-prohibited that matters for my sport?
Red flags specific to this situation
- “Research chemical — not for human use” labels on things sold for human use
- Stacks priced as subscriptions with no monitoring
- Mouse-study citations presented as human evidence
Cost context
A typical commercial peptide-plus-NAD stack runs €200–€600 monthly; none of that spend has demonstrated a human aging outcome. Our intervention pages break down each compound’s actual record.
FAQ
Which longevity compound has the best human evidence?
For hard outcomes, none yet. NAD+ precursors have the most replicated biomarker data; rapamycin has the best animal data with human trials pending.
Is any of this dangerous?
Mostly unknown rather than known-dangerous — which for healthy people is itself the risk calculus to weigh.
→ Build questions for a specific provider · → Cost calculator
Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.